ArticleNeuro-oncology practice2019
Article in Neuro-oncology practice, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Evidence of brain-derived neurotrophic factor in ameliorating cancer-related cognitive impairment: A systematic review of human studies.Critical reviews in oncology/hematology · 2022Pooled it
- Influences on cognitive outcomes in adult patients with gliomas: A systematic review.Frontiers in oncology · 2022Pooled it
- Neurotoxicity from Old and New Radiation Treatments for Brain Tumors.International journal of molecular sciences · 2023Review
- Prognostic and immunomodulatory roles of schizophrenia-associated genes HTR2A, COMT, and PRODH in pan-cancer analysis and glioma survival prediction model.Frontiers in immunology · 2023Article
- A Personalized Longitudinal Strategy in Low-Grade Glioma Patients: Predicting Oncological and Neural Interindividual Variability and Its Changes over Years to Think One Step Ahead.Journal of personalized medicine · 2022Review
- Neural Regulation of Cancer: Cancer-Induced Remodeling of the Central Nervous System.Advanced biology · 2022Review
- Complications, compliance, and undertreatment do not explain the relationship between cognition and survival in diffuse glioma patients.Neuro-oncology practice · 2022Article
- Group-level stability but individual variability of neurocognitive status after awake resections of right frontal IDH-mutated glioma.Scientific reports · 2022Article
- Exercise improves health-related quality of life sleep and fatigue domains in adult high- and low-grade glioma patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Central Nervous System Plasticity Influences Language and Cognitive Recovery in Adult Glioma.Neurosurgery · 2021Review
- The impact of high functional connectivity network hub resection on language task performance in adult low- and high-grade glioma.Journal of neurosurgery · 2021Article
- Prognostic Prediction Model for Glioblastoma: A Metabolic Gene Signature and Independent External Validation.Journal of Cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundCognitive and language dysfunction is common among patients with glioma and has a significant impact on survival and health-related quality of life (HRQOL). Little is known about the factors that make individual patients more or less susceptible to the cognitive sequelae of the disease. A better understanding of the individual and population characteristics related to cognitive function in glioma patients is required to appropriately stratify patients, prognosticate, and develop more efficacious treatment regimens. There is evidence that allelic variation among genes involved in neurotransmission and synaptic plasticity are related to neurocognitive performance in states of health and neurologic disease.
methodsWe studied the association of single-nucleotide polymorphism variations in brain-derived neurotrophic factor (
resultsPatients with higher-performing alleles have better scores on neurocognitive testing with the Repeatable Battery for the Assessment of Neuropsychological Status and Stroop test, but not the Trail Making Test.
conclusionsA better understanding of the genetic contributors to neurocognitive performance in glioma patients and capacity for functional recovery is necessary to develop improved treatment strategies based on patient-specific factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.